 | Does Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Have A Particularly Volatile Share Price?
finance.yahoo.com - March 29 at 5:30 PM |
 | Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) Short Interest Up 40.9% in March
www.americanbankingnews.com - March 28 at 2:10 AM |
| Zacks: Analysts Expect Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) to Announce -$0.66 EPS
www.americanbankingnews.com - March 22 at 4:22 PM |
 | Aeglea BioTherapeutics EPS beats by $0.03
seekingalpha.com - February 24 at 1:59 PM |
| Aeglea BioTherapeutics Reports Fourth-Quarter and Full-Year 2019 Financial Results, Highlights Recent Milestones
finance.yahoo.com - February 24 at 8:58 AM |
| Should Aeglea BioTherapeutics (NASDAQ:AGLE) Be Disappointed With Their 66% Profit?
finance.yahoo.com - February 13 at 7:08 AM |
| Aeglea BioTherapeutics Submits CTA Application for its Novel Engineered Human Enzyme Designed to Treat Homocystinuria (ACN00177)
finance.yahoo.com - January 13 at 4:35 PM |
| Is Aeglea BioTherapeutics, Inc.'s (NASDAQ:AGLE) CEO Salary Justified?
finance.yahoo.com - January 8 at 5:12 PM |
| Aeglea BioTherapeutics to Present at 38th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 6 at 8:29 PM |
| Hedge Funds Are Dumping Aeglea BioTherapeutics, Inc. (AGLE)
finance.yahoo.com - December 12 at 11:55 PM |
| Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Insiders Increased Their Holdings
finance.yahoo.com - December 3 at 6:50 AM |
| Aeglea BioTherapeutics EPS misses by $0.12
seekingalpha.com - November 13 at 12:47 PM |
| Aeglea BioTherapeutics Reports Third Quarter 2019 Financial Results and Corporate Highlights
finance.yahoo.com - November 6 at 1:19 PM |
| Aeglea BioTherapeutics Strengthens Leadership Team with Appointment of Ravi M. Rao as Chief Medical Officer and Michael C. Hanley as Chief Commercial Officer
finance.yahoo.com - November 4 at 1:14 PM |
| Will Aeglea BioTherapeutics (NASDAQ:AGLE) Spend Its Cash Wisely?
finance.yahoo.com - October 10 at 12:13 PM |
 | Aeglea Bio Therapeutics Inc
www.reuters.com - October 2 at 8:43 PM |
| Does Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Have A Volatile Share Price?
finance.yahoo.com - September 5 at 1:57 PM |
| Aeglea BioTherapeutics to Present New 20-Dose Data for Pegzilarginase in Patients with Arginase 1 Deficiency at 2019 SSIEM Symposium
finance.yahoo.com - August 29 at 11:41 AM |
 | Aeglea BioTherapeutics Reports Second Quarter 2019 Financial Results and Corporate Highlights
www.marketwatch.com - August 6 at 10:26 AM |
| Aeglea BioTherapeutics EPS misses by $0.07
seekingalpha.com - August 6 at 10:26 AM |
| Aeglea BioTherapeutics: Investment Potential Addressing Unmet Need
seekingalpha.com - July 30 at 9:51 AM |
| Aeglea BioTherapeutics Receives FDA Breakthrough Therapy Designation for Pegzilarginase for Treatment of Arginase 1 Deficiency
finance.yahoo.com - July 24 at 8:09 PM |
| Can We See Significant Institutional Ownership On The Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Share Register?
finance.yahoo.com - July 17 at 6:09 PM |
| Aeglea Biotherapeutics Inc (AGLE) President & CEO Anthony G. Quinn Bought $196,535 of Shares
finance.yahoo.com - June 15 at 12:13 AM |
| Hedge Funds Have Never Been This Bullish On Aeglea BioTherapeutics, Inc. (AGLE)
finance.yahoo.com - June 12 at 11:25 AM |
| Aeglea BioTherapeutics (AGLE) Presents At Jefferies 2019 Healthcare Conference - Slideshow
seekingalpha.com - June 7 at 4:34 PM |
| Aeglea BioTherapeutics Doses First Patient in Pivotal Phase 3 PEACE Trial of Pegzilarginase in Arginase 1 Deficiency
finance.yahoo.com - June 3 at 8:45 AM |
| Aeglea BioTherapeutics to Participate in Upcoming Investor and Industry Conferences
finance.yahoo.com - May 30 at 8:54 AM |
| Aeglea Biotherapeutics Inc (AGLE) President & CEO Anthony G. Quinn Bought $180,028 of Shares
finance.yahoo.com - May 23 at 8:54 AM |
| Have Insiders Been Selling Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Shares?
finance.yahoo.com - April 27 at 5:19 PM |
| Aeglea BioTherapeutics Announces New Positive Phase 1/2 Data for Pegzilarginase in Patients with Arginase 1 Deficiency at 2019 Annual Meeting of the Society for Inherited Metabolic Disorders
finance.yahoo.com - April 7 at 11:45 PM |
| Aeglea BioTherapeutics to Present Updated Phase 1/2 Data for Pegzilarginase in Patients with Arginase 1 Deficiency in an Oral Presentation at the 2019 Annual Meeting of the Society for Inherited Metabolic Disorders
finance.yahoo.com - April 1 at 8:58 AM |
| Aeglea BioTherapeutics to Participate in Upcoming Investor Conferences
finance.yahoo.com - March 28 at 9:04 AM |
 | Aeglea BioTherapeutics Inc
www.bloomberg.com - March 19 at 9:10 AM |
| Edited Transcript of AGLE earnings conference call or presentation 7-Mar-19 9:30pm GMT
finance.yahoo.com - March 9 at 8:37 AM |
| Aeglea BioTherapeutics' (AGLE) CEO Anthony Quinn on Q4 2018 Results - Earnings Call Transcript
seekingalpha.com - March 8 at 8:58 AM |
| Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights
finance.yahoo.com - March 7 at 6:34 PM |
| The Aeglea BioTherapeutics Share Price Is Up 11% And Shareholders Are Holding On
finance.yahoo.com - March 6 at 7:02 PM |
| Aeglea BioTherapeutics to Host Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights Conference Call
finance.yahoo.com - February 28 at 8:58 AM |
| Aeglea aims to raise $60M for treating rare diseases
finance.yahoo.com - February 7 at 6:18 PM |
| Aeglea Biotherapeutics prices $60M equity offering
seekingalpha.com - February 6 at 8:59 AM |
| Aeglea BioTherapeutics Announces Pricing of $60.0 Million Public Offering
finance.yahoo.com - February 6 at 8:59 AM |
| How Much Of Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) Do Institutions Own?
finance.yahoo.com - January 29 at 5:51 PM |
| Is Aeglea BioTherapeutics, Inc. (AGLE) A Good Stock To Buy?
finance.yahoo.com - December 23 at 8:33 AM |
| What Investors Should Know About Aeglea BioTherapeutics, Inc.’s (NASDAQ:AGLE) Financial Strength
finance.yahoo.com - December 14 at 5:21 PM |
